Nonetheless, medicinal chemists and pharmaceutical scientists hope to improve the quality of life of AD patients by creating innovative immunotherapy approaches using well-designed antibodies targeting AD-relevant tau species. This evidence concerns the gene MAPT and Alzheimer disease.